Deep Brain Stimulation In Parkinson’s Disease Market (2025 - 2030)

Market Size & Trends

The global deep brain stimulation in Parkinson’s disease market size was valued at USD 909.6 million in 2024 and is projected to grow at a CAGR of 10.1% from 2025 to 2030. This growth is driven by the increasing prevalence of Parkinson's disease and other neurological disorders that necessitate advanced treatment options such as deep brain stimulation (DBS). Additionally, the rising geriatric population, which is more susceptible to Parkinson's disease, contributes significantly to the market growth. Technological advancements in DBS devices, such as improved microelectrode designs and robot-assisted implantation, are enhancing the effectiveness and safety of the treatment.

Government policies and laws play a crucial role in supporting the deep brain stimulation (DBS) market for Parkinson's disease through various initiatives aimed at enhancing research, funding, and access to treatment. Increased funding for research by government agencies, such as the National Institute of Neurological Disorders and Stroke (NINDS), facilitates clinical trials that assess the safety and efficacy of DBS devices, thereby encouraging innovation in this field. Additionally, favorable reimbursement policies by programs such as Medicare and the National Health Service (NHS) improve patient access to DBS therapy, making it more financially viable for healthcare providers to offer these advanced treatments.

Moreover, regulatory reforms aimed at streamlining the approval process for medical devices can significantly reduce barriers to market entry, allowing new DBS technologies to reach patients more quickly. For instance, the FDA has introduced pathways such as Early Feasibility Studies to support clinical investigations in smaller populations, which is particularly beneficial for rare disease treatments.

Product Insights

The dual-channel segment accounted for the largest share of 56.9% in 2024 due to dual-channel’s superior effectiveness in reducing patient tremors and enhancing the overall quality of life. Dual-channel DBS devices offer greater control and precision in delivering electrical stimulation to the targeted brain regions, making them highly preferred by neurosurgeons and patients alike. The robust performance and reliability of dual-channel systems have cemented their dominant position in the market.

The single-channel segment is expected to grow at a CAGR of 10.3% from 2025 to 2030, owing to the increasing demand for minimally invasive treatments and advancements in single-channel DBS technology. Single-channel devices are becoming more sophisticated, offering improved outcomes with fewer complications2. The segment's growth is also driven by the rising prevalence of Parkinson's disease and the need for cost-effective treatment options.

End-use Insights

The hospital segment dominated the market in 2024. Hospitals are often equipped with advanced medical technology and specialized personnel, enabling them to provide comprehensive care for patients requiring DBS therapy. The complexity of the procedure and the need for continuous monitoring and support throughout the treatment process make hospitals the preferred setting for many patients. Moreover, hospitals typically offer a multidisciplinary approach, combining neurologists, neurosurgeons, and other healthcare professionals, which enhances patient outcomes through coordinated care. As Parkinson’s disease often presents with a range of symptoms requiring ongoing management, hospitals are well-positioned to provide the integrated care necessary for effective treatment.

The Ambulatory Surgical Centers(ASCs) segment is projected to grow the fastest over the forecast period. ASCs provide a less complex and more cost-effective alternative to hospitals for surgical procedures, including DBS. Patients increasingly seek outpatient options that allow for quicker recovery times and lower overall healthcare costs. ASCs are often more efficient in terms of scheduling and can offer a streamlined experience, minimizing wait times and enhancing patient satisfaction. Furthermore, advancements in minimally invasive techniques and technologies in the field of neuromodulation are making it possible for procedures such as DBS to be performed safely in an outpatient setting. This shift not only improves accessibility for patients but also aligns with the growing trend of outpatient care across various medical specialties.

Regional Insights

North America DBS in the Parkinson’s disease market dominated the largest revenue share in 2024. The region's dominance can be attributed to several factors, including the high prevalence of Parkinson’s disease, advanced healthcare infrastructure, and significant government and private funding for research and development. Technological advancements, such as robot-assisted implantation and enhanced microelectrode designs, have further propelled the market growth in this region.

U.S. DBS In Parkinson’s Disease Market Trends

The U.S. DBS in the Parkinson’s disease market accounted for 88.1% of revenue of the North American market in 2024 driven by factors such as the increasing prevalence of Parkinson’s disease, technological advancements in DBS devices, and substantial government funding for research and development. The National Institute of Neurological Disorders and Stroke (NINDS) has been a significant contributor, providing substantial financial support for PD research.

Europe Deep Brain Stimulation In Parkinson’s Disease Market Trends

Europe's DBS in Parkinson’s disease market is projected to grow at a CAGR of 10.5% from 2025 to 2030 fueled by increasing awareness of DBS therapy, rising prevalence of Parkinson’s disease, and supportive government policies. The region is witnessing a surge in demand for advanced DBS devices, driven by the aging population and the need for effective treatment options for neurological disorders1. European countries are also investing in research and development to improve DBS technologies and make them more accessible to patients.

Asia Pacific Deep Brain Stimulation In Parkinson’s Disease Market Trends

The Asia Pacific DBS in Parkinson’s disease market is anticipated to grow fastest throughout the forecast period. This rapid growth can be attributed to the increasing prevalence of Parkinson’s disease, rising healthcare expenditure, and growing awareness about DBS therapy. The region is also benefiting from technological advancements and the introduction of innovative DBS devices. Governments in the Asia Pacific region are actively supporting the adoption of DBS therapy through favorable policies and funding for research and development.

Key Deep Brain Stimulation In Parkinson’s Disease Company Insights

Some of the key companies in the deep brain stimulation In Parkinson’s disease market include ABBOTT, Medtronic, Boston Scientific Corporation, and others.

• Medtronic plc has been a pioneer in the deep brain stimulation (DBS) market, being the first company to receive FDA approval for a DBS device for Parkinson's disease back in 1997. Its Activa line of devices includes both rechargeable and non-rechargeable batteries, catering to different patient needs. In 2020, Medtronic launched the Percept device, which stands out as the first DBS system capable of sensing and recording brain signals, allowing for more precise adjustments based on individual patient responses. Recently, Medtronic received FDA approval for Asleep DBS surgery for Parkinson's and essential tremor patients.

• Abbott is a prominent player in the deep brain stimulation (DBS) market for Parkinson's disease, particularly known for its Infinity DBS system. This system is unique as it is the first directional DBS device approved for all major targets used in treating movement disorders, including the internal globus pallidus (GPi), which is crucial for managing Parkinson's symptoms. Abbott's Infinity system utilizes advanced technology, including an iOS software platform, allowing clinicians to program the device using an iPad mini, enhancing efficiency in patient management.

Recent Developments

• In August 2024, Medtronic plc received FDA approval for Asleep DBS surgery for Parkinson's and essential tremor patients. This innovative approach allows patients to undergo DBS surgery either awake or asleep, providing greater flexibility and comfort.

Deep Brain Stimulation In Parkinson’s Disease Market